Mochizuki M, Ikeda E, Yoshimura K, Hikita N, Nagata Y, Iwamoto A, Fujino Y, Eguchi S, Oka S, Kimura S
Department of Ophthalmology, Kurume University School of Medicine, Fukuoka-ken, Japan.
Nippon Ganka Gakkai Zasshi. 1998 Aug;102(8):515-21.
Active cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) was treated with an intraocular sustained-release ganciclovir implant. A total number of 19 implants were performed in 15 eyes of 9 AIDS patients. The intraocular sustained-release ganciclovir was effective in preventing reactivation of CMV retinitis in 15 of the 19 implants, ineffective in 3, and undetermined in 1. All ineffective cases had been resistant to ganciclovir therapy before the implants. Vision after the therapy was maintained at better than 0.5 except for one eye. There were no serious ocular complications caused by the therapy. Among 5 patients with unilateral CMV retinitis, 2 unaffected eyes developed CMV retinitis during this therapy. In addition, another patient developed presumed CMV infection in other systemic organs. Based on these data, the intraocular sustained-release ganciclovir implant was considered to be useful for the treatment of CMV retinitis in AIDS.
对获得性免疫缺陷综合征(AIDS)患者的活动性巨细胞病毒(CMV)视网膜炎采用眼内缓释更昔洛韦植入物进行治疗。9例AIDS患者的15只眼中共植入了19个植入物。眼内缓释更昔洛韦在19个植入物中的15个中有效预防了CMV视网膜炎的复发,3个无效,1个效果未明。所有无效病例在植入前对更昔洛韦治疗均耐药。除一只眼外,治疗后的视力维持在0.5以上。该治疗未引起严重的眼部并发症。在5例单侧CMV视网膜炎患者中,2只未受影响的眼睛在该治疗期间发生了CMV视网膜炎。此外,另一名患者在其他全身器官出现了疑似CMV感染。基于这些数据,眼内缓释更昔洛韦植入物被认为对治疗AIDS患者的CMV视网膜炎有用。